August 31, 2015 Bristol-Myers Squibb has bought rights to a fibrosis drug and its privately held developer – Promedior. The deal gives Bristol-Myers access to Promedior Inc’s lead experimental drug, PRM-151, which is being tested in myelofibrosis as well as diopathic pulmonary fibrosis. Promedior’s mid-stage studies of its fibrosis drug are expected to begin in… Read More »BMS BUYS RIGHTS TO PRM-151 AND PROMEDIOR
August 18, 2015 You may have noticed a change to our logo and tagline, which went live Tuesday August 18th. Our new logo is bolder, with a tagline to match. The updated logo for MPN Research Foundation accompanies the tagline, “Change your prognosis”, which articulates the essence of what the organization is here for. We… Read More »LET’S CHANGE YOUR PROGNOSIS
August 14, 2015 An article in Modern Pathology by Marco Pizzi, Richard T Silver, Ariella Barel and Attilio Orazi discussed their findings from a retrospective study, that recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis. The authors conclude by saying that further research is needed to confirm this preliminary data. Click here to read more.
August 11, 2015 “The best thing we can do as a patient-driven organization funding our own research is to entice the best minds in science to focus on PV, ET and MF lest they get left by the wayside” says MPN Research Foundation President Barbara Van Husen. It is on that note we are proud… Read More »2015 MPN CHALLENGE GRANT AWARDS
August 6, 2015 On July 28th we shared a story on Facebook about an initiative including dozens of blood cancer thought leaders who joined together to support a petition to lower the cost of cancer drugs. An article in Mayo Clinic Proceedings requests a patient-initiated drive to reduce the costs of cancer drugs included reasonable solutions that could work… Read More »LEADERS FROM THE MPN MEDICAL COMMUNITY TAKE ON THE HIGH COST OF CANCER DRUGS
August 1, 2015 We are pleased to announce that effective 8/1/2015, Michelle Woehrle has assumed the role of Executive Director of the MPN Research Foundation. Michelle began working with the Foundation in 2007, and since that time her role has expanded to include oversight of office administration, financial management, grant program support and coordination of… Read More »EXECUTIVE DIRECTOR
June 25, 2015 Galena presented Phase 2 data on Gale-401: PHASE 2 STUDY OF A NOVEL CONTROLLED-RELEASE FORMULATION OF ANAGRELIDE (GALE-401) IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN)-RELATED THROMBOCYTOSIS Prof. Dr. Heinz Gisslinger presented a poster on CALR and ASXL1 mutations: IMPACT OF CALR AND ASXL1 MUTATIONS ON SURVIVAL AND DISEASE COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PREFIBROTIC PRIMARY… Read More »2015 EHA NEWS ON MPNS
On August 19, 2014, Julie Libon was diagnosed with Myelofibrosis. She learned that MF is a rare blood cancer that affects approximately 16,500 to 18,000 people in the United States with no cure and no treatments to slow down the progression of this disease. After her diagnosis, she and her family felt compelled to act.… Read More »WITH RESEARCH THERE IS HOPE
une 5, 2015 The American Society of Clinical Oncology has its big meeting each year in Chicago in early June. In the past solid tumor cancers have received the most attention, saving blood cancer announcements for the American Society of Hematology meeting where the focus is more narrow. This year, however, was different, with big… Read More »2015 ASCO NEWS
February 25, 2015 Last week we issued a call for proposals for our 2015 grant program, which we run with with some help from the Leukemia & Lymphoma Society, but is largely funded by patients around the world. Our place in the growing world of MPN research is to seek out new ideas that are… Read More »PROMISE AND POSSIBILITY
